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Minireview
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Abstract
Peripheral arterial occlusive disease (PAOD) contributes to decreased exercise tolerance, poor balance, impaired proprioception,
muscle atrophy and weakness, with advanced cases resulting in critical limb ischemia (CLI) where the viability of the limb is
threatened. Patients with a diagnosis of CLI have a poor life expectancy due to concomitant cardio and cerebrovascular diseases.
The current treatment options to avoid major amputation by re-establishing a blood supply to the limb generally have poor
outcomes. Human skeletal muscle contains both multipotent stem cells and progenitor cells and thus has a capacity for regen-
eration. Phase I and II studies involving transplantation of bone marrow-derived progenitor cells into CLI limbs show positive
effects on wound healing and angiogenesis; the increase in quiescent satellite cell numbers observed in CLI muscle may also
provide a sufficient in vivo source of resident stem cells. These indigenous cells have been shown to be capable of formingmultiple
mesodermal cell lineages aiding the repair and regeneration of chronically ischemic muscle. They may also serve as a repository
for autologous transplantation. The behavior and responses of the stem cell population in CLI is poorly understood and this review
tries to elucidate the potential of these cells and their future role in the management of CLI.
Keywords: Critical limb ischemia, peripheral arterial occlusive disease, stem cells, satellite cells
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Introduction
Peripheral arterial occlusive disease (PAOD) contributes to
decreased exercise tolerance, poor balance, impaired pro-
prioception, muscle atrophy and weakness, with
advanced cases resulting in critical limb ischemia (CLI).
Patients with CLI suffer from rest pain, ulceration and
gangrene, which results in perigenicular amputation if
severe or where revascularization fails.1 The presence of
CLI is such a poor prognostic indicator that within the
first year of diagnosis around 25% of patients will die
from a cardiac or cerebrovascular incident. In this time
period around 30% of patients will undergo a perigenicu-
lar amputation and about 20% will endure unrelenting
pain or tissue loss.2,3
Generally, these patients are high-risk surgical candi-
dates with multiple co-morbidities and poor mobility.2,3
Current treatment options to avoid limb loss by re-establish-
ing in line blood supply to the limb are limited, with poor
outcomes predicted by multilevel arterial disease and a lack
of sufficient runoff vessels supplying the distal limb.
Percutaneous transluminal angioplasty (PTA) is less inva-
sive than bypass surgery, but nevertheless has its risks and
limitations and there is an overall peri-procedural morbid-
ity rate of 5%.4,5
In those patients in whom traditional surgery or PTA has
failed or is inappropriate, one of the remaining options is
therapeutic angiogenesis. The administration of angiogenic
agents or stem cells directly into affected muscle has shown
some early promise.6–12 Human skeletal muscle has an
impressive capacity for regeneration due to the different
stem cells and progenitor cells residing within it. A clear
understanding of the behavior of these stem cells, their abil-
ity to repair, regenerate and self-renew in ischemic condi-
tions may lead to potential therapeutic strategies involving
these multipotent cells in preventing, treating or even
reversing the damage caused by atherosclerosis.
Satellite cells
One of the most studied stem cells in skeletal muscle is the
satellite cell, originally identified as a bipotent myogenic
precursor cell, which was first recognized in the sartorius
muscle of the frog and named by Alexander Mauro in
1961.13 These cells were observed under electron micro-
scope as a distinct population of cells, lying above the
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muscle fiber sarcolemma but beneath the fiber basal lamina,
and accounting for up to between 3 and 6% of visible myo-
nuclei seen,14 see Figure 1. Their structure was found to be
completely different to muscle cells, being mononucleate
with large nuclei and a relatively small amount of inde-
pendent cytoplasm. Under light microscopy, satellite cells
may be distinguishable from myonuclei due to their loca-
tion, smaller size and greater nuclear content.15 The general
dimensions of a quiescent satellite cell in mammalian skel-
etal muscle measure around 25 mm in length, 4 mm in height
and 5mm in width.16
Destruction of satellite cells in adult small mammals via
gamma irradiation leads to retarded muscle growth,
demonstrating that they are required for normal skeletal
muscle maintenance.17–19 Satellite cells therefore are the
myogenic precursor cells of postnatal muscle and are
responsible for the repair and regeneration of muscle
fibers in adult tissue, either by fusing together and forming
new fibers or incorporating themselves into damaged
muscle cells and their myonuclei.20 Plasticity of muscle
fibers is influenced locally by satellite cells under the
control of the muscle regulatory factors (MRFs – see
Figure 2).21–23
These cells are possibly the only significant source of
new myoblasts in the adult tissue, but the contribution of
other cells such as bone-derived hematopoietic cells, vascu-
lar progenitor cells, or interstitial cells has yet to be fully
elucidated.24 The coordinated action of these cells is
required for the process of plasticity in the form of pre-
conditioning, remodeling of muscle through fiber shift
and the efficient repair of damaged myofibers. This occurs
in ischemic tissue and although studies vary in their find-
ings regarding which fibers are the most resilient in the face
of advancing ischemia, they generally concur that the
regenerative capacity of muscle becomes exhausted with
worsening disease. In younger adults, this regenerative
activity is well regulated, but tight coordination breaks
Figure 1 A quiescent satellite cell seen at22,200 magnification (scale bar in nanometers) with a transmission electron microscope. The skeletal muscle biopsy was
known to be from critically ischaemic tissue. Of note, a single large nucleus is visible with a prominent but small nucleolus and little cytoplasm. The membrane of the
satellite cell is smooth with no projections indicating quiescence
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down in advancing disease and individual satellite cells
may act independently of normal cues.25
Satellite cells cannot be detected by a single antibody as
they express different proteins at different points in their
cell cycle.26 Table 1 shows the markers in common use.
Active, quiescent and proliferating satellite cells express
pax7, a paired-box transcription factor that has a molecular
weight of 57 kDa and is essential for the mitogenesis of
these cells. It is co-expressed with MyoD or myf-5 in acti-
vated satellite cells but is not present in cells expressing
myogenin. Quiescent satellite cells are pax7þ/CD34þ/
MyoD.27 Myf-5/CD34/pax7þve cells are thought to iden-
tify the majority of the quiescent committed population, but
around 20% of non-committed satellite cells may not be
recognized by these markers.19 Myf-5 is a transcription
factor essential for the activation of satellite cells and
CD34 is a marker of hematopoietic stem cells (HSCs) and
is required for maintaining the quiescent state of myogenic
stem cells.28M-cad strongly expressed by the immature
myoblast is a morphoregulatory calcium-dependent cell
adhesion protein intrinsic to myogenesis and is located at
the myofiber/satellite cell junction.
Quiescent satellite cells as seen in Figure 3, are activated
by the presence of a damaged basal laminar structure, with
the integrity of the basal lamina being more important than
previously thought. In a variety of animal models where
muscle is damaged by crushing,29 freezing30 or injection
with toxins,31 the satellite cell response appears to follow
two paths; dependent not on the mode of injury but upon
whether or not the basal lamina is intact. Figure 3 demon-
strates those factors responsible for the activation of quies-
cent satellite cells. When the basal lamina is intact, activated
satellite cells contained within this layer migrate to the site
of injury in the same muscle fiber via chemotaxic sti-
muli.17,31 Activation of cells has been reported at around
6 h post-injury and within 24 h the cells display significant
mitosis.29 The satellite cell then merges with the myofiber
and helps repair or regenerate either myofiber material,
contribute to existing myonuclei or replenish the satellite
cell population20 and this process is schematically repre-
sented in Figure 2. In injuries where there is disruption of
the basal lamina, satellite cells are able to migrate from adja-
cent myofibers by projecting across tissue bridges initiated
from an out-pouching process of the satellite cell itself.17,32
This suggests that whatever the etiology of muscle damage,
the processes of repair and regeneration are the same.
Aside from basal laminar disruption, other activators of
satellite cells include migrating inflammatory cells, medi-
ators such as nitric oxide (NO), the MRFs such as myf-5,
specific extracellular signaling through Wnt, IL-6 and the
insulin-like growth factors (IGFs)33 as seen in Figure 3.
These lead to myoblastic proliferation, but differentiation
is retarded, due to the inhibition of the Notch system. It
has been determined that the IGF-1 splice variant known
as mechano growth factor (MGF) is expressed by damaged
myoblasts and initiates the activation of satellite cells.34 In
healing tissue, expandingmyoblasts closely interact and are
under the control of nearby inflammatory and stromal cells.
Active satellite cells or myogenic precursors contribute to
mature post-mitotic myofibers after stimulation by IGF-1ea,
another splice variant of IGF-1.33–36
Animal experiments have demonstrated that exercise-
induced ischemia can increase the proportion of satellite
cells and myonuclei.37 The activation of satellite cells in
response to such training ensures that the proportionate
number of myonuclei per fiber remains constant, allowing
continuing control despite the increase in fiber size and
number. This is reflected in the increasing number of myo-
nuclei seen in exercise-induced muscle hypertrophy, whilst
a loss of myonuclei is observed occurring during atrophy.38
The frequency of satellite cells is not known to differ
according to their location within a muscle or around any
specific fiber type.39 Larger myofibers have more satellite
cells suggesting each satellite cell has a ‘‘sphere of influ-
ence.’’ This becomes less organized with age as the
nuclear domains governed by the myonuclei enlarge
and satellite cell numbers decrease.40 Satellite cell prolif-
eration has also been reported as increasing due to the
following: denervation, youth, endurance exercise, low-
frequency electrical stimulation, stretch, testosterone and
immobilization.24,37,41–45
In vivo studies demonstrate a decline in the satellite cell
population with age.25,46 Coupled with this reduced cap-
acity in the older population, nerve degeneration and a
reduction in myofiber cytoplasm to nucleus ratio intrinsic
within the fibers (leading to volume loss), is also
observed.30,31 It is unclear whether the number of satellite
cells or their regenerative potential is the greatest limit on
their ability to repair and regenerate, although both are
implicated. Some studies report a decrease in satellite cell
numbers in skeletal muscle with advancing age41,47–49 while
others also observed a decrease in their regenerative poten-
tial.25,41,47,48 There have been few reports regarding satellite
cell number and behavior in critically ischemic skeletal
muscle, but it seems likely that the intrinsic activated
stem cells are overwhelmed by the extent of advanced
ischemic disease on a background of limited regenerative
capacity due to age. Although originally identified as bipo-
tent, i.e. capable of self renewal or forming myoblasts, there
is increasing evidence that satellite cells, like bone marrow-
derived mesenchymal stem cells, are capable of regenerat-
ing most other tissue types – see Figure 2 – given the right
stimuli.50 When transplanted from skeletal muscle into
infarcted cardiac muscle, satellite cells can regenerate the
Table 1 Markers of satellite cells at different stages in cell cycle: (45)
Marker Quiescent Active
Differentiating
myoblast/proliferating SC
Cell surface antigens
CD34 þ þ 
c-met þ þ þ
M-cadherin þ þ þ
Transcription factors
myf5 þ þ þ
MyoD  þ þ
pax7 þ þ 
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cardiomyocytes adjacent to them51; however, due to a
decrease of the adhesion molecules N-cadherin and con-
nexin 43, the regenerated cells do not perform entirely in
concert with the rest of the myocardium52,53 and may
impair remodeling and cardiac function.54 Pioneering stu-
dies transplanting cells into ischemic tissue, particularly
cardiac muscle, have given us some insight into their behav-
ior; but more in vitrowork isolating different stem cells and
observing them in chronically hypoxic conditions is
required in order to understand the factors that may pro-
mote their activation.10 Skeletal muscle itself has vast regen-
erative potential; yet whilst resident cells in skeletal muscle
may proliferate, differentiation is inhibited and the
regenerative potential of these cells seems to be over-
whelmed by advancing disease or ischemia. The prolifer-
ation of satellite cells in ischemic tissue with disordered
differentiation is similar to the response of angiogenic
cells in advanced ischemia.
Alternate stem cells
HSCs, or side population cells (SPCs), may be capable of
replenishing the population of resident stem cells by
migrating beneath the basement membrane. Other sources
of such mesenchymal stem cells, or multipotent adult pro-
genitor cells (MAPCs)55 can be identified using the nestin
antigen and include osteoblasts, endothelial cells and
Figure 2 Schematic diagram demonstrating the role of the satellite cell, as a bipotent stem cell, contributing to myofibers, myonuclei or self renewal of the satellite
cell population. In CLI, quiescent satellite cell numbers increase, demonstrating that proliferation occurs in abundance but maturation and terminal differentiation are
inhibited
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mesoangioblasts. Nestin is an intermediate filament protein
found in both nerve and muscle cells, but most importantly
has been shown to be present in progenitor cells, such as
muscle-derived satellite cells or HSCs and is therefore
useful as a cell marker.56 Establishing the precise role of
HSCs is difficult and there are unanswered questions
regarding the origin of these multipotent cells, which
have been stimulated to differentiate not only into hemato-
poietic lineages but also hepatocytes,57 cardiomyocytes,51,58
renal tubules59 and gastrointestinal epithelial and vascular
endothelial cells.60,61 Increased numbers of HSCs, identified
by antigen markers such as CD34, have been observed in
CLI muscle.62,63 Despite the presence of more than one type
of stem cells, repair of ischemic tissue is inadequate, sug-
gesting that the cells identified are either incapable of
repairing ischemic tissue or are unable to differentiate
into mature and organized tissue types.
Other stem cells present include inflammatory mono-
cytes and resident fibro-adipogenic progenitors (FAP),
which have been demonstrated to assist in the myogenic
response.35,36 These cells may also modulate the behavior
of satellite cells. Both FAPs and bone marrow-derived
monocytes have been shown to inhibit normal haematopoi-
etic stem and satellite cell differentiation and thus they inhi-
bit normal function.64 FAPs proliferate in skeletal muscle
tissue when myogenic precursor cells fail to undergo
normal myogenic differentiation due to disease processes
or age-limited mitogenesis or lipofuscin accumulation.64
Chronic damage such as that caused by ischemia may
result in fatty degeneration when muscle atrophies and dis-
order are further complicated by the accumulation of white
adipose cells and fibrocytes, reducing the ability of the
affected tissue to restore its function.
It has been demonstrated that fibro-adipocytes form
multi-mesenchymal lines, including HSCs,65 neuronal
cells66 and myogenic precursors67 as well as fibrocytes
and adipocytes35,36,64,67,68 represent an exciting source of
multipotent cells.69,70 They also have a regulatory effect
on other stem cell types. Adipose-derived stem cells have
been successfully and safely implanted in patients with CLI
and evidence from a Korean trial (n¼ 15) published in 2012
showed that there was a significant clinical improvement in
two-thirds of patients as measured by pain scores, amputa-
tion rates, claudication distance and appearance on
angiography.71
Future applications
The knowledge that stem cells may be safely harvested and
preserved cryogenically72,73 offers a method of storing mul-
tipotent cells to be administered as autologous transplants
Figure 3 Factors responsible for activation of satellite cells. A multitude of factors including cells, growth factors, hormones and neurotransmitters can activate
resident satellite cells. In this figure, a satellite cell, recognizable from its anatomical position under the basal lamina of the sarcolemma of the muscle fiber, is stimulated
by a wide variety of cytokines and growth factors such as the family of insulin-like growth factors, (IGFs) also including mechano growth factors (MGFs), as well as tissue
growth factor (TGF), platelet derived growth factor, hepatocyte growth factor and fibroblast growth factor have been demonstrated in activating quiescent satellite cells.
Hypoxia (and ischaemia) likely mediated by HIF-1 a (hypoxia inducible factor) and nitric oxide (NO) has also been shown to stimulate these cells
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when required to treat diseases developed later in life. Stem
cells have already been harvested and grown in vitro to be
delivered back to the patient as intravenous or intramuscu-
lar infusions7,74 The US National Institute of Health website
details numerous phase I and II trials underway to assess
the success of using differing stem and progenitor cell
types. The results of studies assessing the performance of
CD34þ cells (Losordo), CD133þ cells (SCRIPT-CLI Trial),
bone marrow-derived mononuclear cells (JUVENTAS IIa),
bone marrow concentrate, bone marrow-derived mesen-
chymal stem cells, angiogenic cell precursors and even mes-
enchymal-stem-cell-like endometrial cells in CLI are
eagerly awaited.
Not only is there a wealth of evidence that stem cells are
implantable, but this has been achieved intravenously,
intramuscularly, via intra arterial (IA) catheters, engrafting
or bone marrow transplantation.7,53,74,75 Recent evidence
suggests that regardless of the mode of transplantation,
stem cells have been identified in all tissues of the donor
body after just a few hours. Current evidence also suggests
that IM or IA routes of administration are as effective as
each other.76
Similar to conditions such as Duchenne muscular dys-
trophy (DMD) where muscle wasting and atrophy are
caused by a defective gene coding for the protein dys-
trophin (which is necessary for normal muscle function),
CLI causes a similar loss of form and function and results
in typical pathognomonic changes such as fiber atrophy,
loss of polygonal structure, fiber clumping, fiber size vari-
ability, fiber loss and other structural abnormalities. In
animal models of DMD, HSCs have been injected intraven-
ously into mdx mice and the complete restoration of the
hematopoietic system and the incorporation of donor-
derived nuclei into myofibers have been observed with par-
tial restoration of dystrophin expression in the affected
muscle.20
Phase I and II studies of stem cells harvested from dis-
parate tissues and in turn administered to critically ische-
mic human skeletal muscle as a strategy to improve limb
perfusion and tissue healing, have shown some early prom-
ise. Progenitor cells from such disparate tissues have similar
characteristics and given the right stimuli are able to fulfill a
multipotent fate.50 Bone marrow-derived progenitor cells
are found freely circulating and may be recruited to assist
in the regeneration of tissue.
In a recent phase I clinical trial, combinations of bone
marrow-derived stem cells containing endothelial progeni-
tor cells and mesenchymal stem cells were administered
intramuscularly to the gastrocnemius muscles of a small
number of patients with CLI.7 The results were an improve-
ment in exercise tolerance (3.48 1.72 fold increase in seven
out of 10 patients, with the others limited by a non-treated
leg in bilateral disease), improved Ankle Brachial Pressure
Index (ABPI) within one month of therapy until cessation of
follow-up at 10 2 months (0.34 0.19 initially to
0.69 0.18 at (P< 0.002), increased transcutaneous oxygen
levels (TcO2 33 6mmHg at baseline to 46 10mmHg) and
all patients reported an improvement in Quality of Life
scores. Angiograms (P¼ 0.002) and perfusion scans were
also assessed and objective improvements were
demonstrated.7
Bone marrow-derived mononuclear cells have also been
injected intramuscularly deep to the ulcers of type II dia-
betics with CLI; these cells shortened recovery times by up
to a month, improving claudication symptoms, raising
TcO2, normalizing ABPIs and demonstrating magnetic res-
onance angiography proven angiogenesis.7,74
Transplantation of embryonic stem cells in this way has
also demonstrated that they not only promote tissue
repair but also replenish the resident satellite cell pool.7,74,77
The recently published phase II randomized controlled
trial ‘‘Use of Vascular Repair Cells (VRC) in Patients with
Peripheral Arterial Disease to Treat Critical Limb Ischemia’’
(RESTORE-CLI; n¼ 72) has shown some encouraging signs
that stem cells promote faster healing and improve clinical
outcomes.78 The trial did not demonstrate any adverse
effects due to the intramuscular injection of autologous
bone marrow-derived tissue repair cells. The study did
show a significant lengthening in the ‘‘time to treatment-
failure,’’ (determined as doubling of ulceration, major
amputation or new gangrene; P¼ 0.0032) and although
‘‘amputation free survival’’ was reduced by 32% this was
not found to be significant (P¼ 0.3880) for the relatively low
number of patients recruited.79
Although stem cells appear to be relatively safe in the
majority of recipients, like many medical interventions
there have been reported failings or adverse effects. A
recent aborted Swedish trial of autologous peripheral
blood mononuclear cells to treat CLI demonstrated that of
the small number of participants included (n¼ 9); four
patients suffered major morbidity or mortality as a direct
consequence of bone marrow stimulation. Two suffered
myocardial infarctions (one fatal), there was one death
from heart failure and another from a massive mesenteric
thrombosis, all forcing the researchers to terminate the
study prematurely.80 An increased frequency of ventricular
arrhythmias has been previously been reported with the
use of cardiac-implanted skeletal myoblasts81–84 suggesting
that stem cell transplantation may not always be appropri-
ate and until their safety and efficacy are better understood
universal therapeutic application should be approached
with caution.
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